Stay updated on Pembrolizumab with BCG in HR NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab with BCG in HR NMIBC Clinical Trial page
- Check7 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2. No visible changes to page content or layout.SummaryDifference0.0%

- Check14 days agoChange DetectedRevision tag updated from v3.4.0 to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded UI elements and metadata: Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed the older items Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision history updated: added v3.3.4 and removed v3.3.3.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded registry identifiers U1111-1282-1555 and 2022-501817-29-00. Replaced old EngageZone data-sharing references with trialstransparency.msdclinicaltrials.com and externaldatasharing-msd.com.SummaryDifference0.2%

- Check63 days agoChange DetectedThe Locations section now includes a large expansion of study sites across multiple countries and regions, listing new sites in the US, Canada, Europe, Asia, Australia, and South America. Several previously listed sites have been removed.SummaryDifference4%

Stay in the know with updates to Pembrolizumab with BCG in HR NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.